Home » SUN PHARMA EYES 7-FOLD RISE IN US PRODUCT LAUNCH
SUN PHARMA EYES 7-FOLD RISE IN US PRODUCT LAUNCH
Sun Pharmaceutical Industries Ltd. forecast a seven-fold jump in U.S. product
launches next year and detailed the spin-off of its research and development unit.
Shareholders in the company, which spends a relatively high 12 per cent of sales
on R&D, will receive equal shares in its R&D unit and remaining generic
drug business, Sun Pharma Managing Director Dilip Shanghvi said at the Reuters
India Summit on Monday.
Sify
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May